Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Disease, Residual”

474 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 474 results

Testing effectiveness (Phase 2)Ended earlyNCT03298412
What this trial is testing

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Who this might be right for
High-risk Diffuse Large B-cell Lymphoma
Amgen 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04071457
What this trial is testing

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Who this might be right for
Multiple Myeloma
SWOG Cancer Research Network 1,100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05554419
What this trial is testing

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04521231
What this trial is testing

Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Who this might be right for
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen 181
Not applicableNot Yet RecruitingNCT06854939
What this trial is testing

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

Who this might be right for
NSCLC, Stage I, II, III
National Cancer Center, Japan 350
Testing effectiveness (Phase 2)WithdrawnNCT04944173
What this trial is testing

SCION: SABR and Checkpoint Inhibition of NSCLC

Who this might be right for
Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNon-small Cell Lung Cancer Stage I+4 more
University of British Columbia
Testing effectiveness (Phase 2)Looking for participantsNCT05735717
What this trial is testing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaRemission+21 more
Masonic Cancer Center, University of Minnesota 70
Not applicableStudy completedNCT03521596
What this trial is testing

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS

Who this might be right for
Waldenstrom Macroglobulinemia
Fondazione Italiana Linfomi - ETS 300
Not applicableLooking for participantsNCT06653062
What this trial is testing

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

Who this might be right for
Hepatocellular Carcinoma (HCC)
Tongji Hospital 50
Not applicableLooking for participantsNCT06463717
What this trial is testing

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Who this might be right for
Multiple MyelomaMinimal Residual Disease
First Affiliated Hospital of Zhejiang University 210
Not applicableLooking for participantsNCT06230185
What this trial is testing

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Personalis Inc. 422
Not applicableStudy completedNCT03627208
What this trial is testing

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

Who this might be right for
Leukemia, Lymphoblastic, AcuteALL, Childhood
National Cancer Institute (NCI) 150
Not applicableStudy completedNCT02888145
What this trial is testing

Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic Pathology

Who this might be right for
Neoplastic PathologyAutopreserved Ovarian Tissue
Centre Hospitalier Universitaire de Besancon 240
Not applicableStudy completedNCT00339898
What this trial is testing

Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma

Who this might be right for
Non-Metastatic Ewings Sarcoma
National Cancer Institute (NCI) 414
Early research (Phase 1)Not Yet RecruitingNCT07720843
What this trial is testing

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Montefiore Medical Center 50
Not applicableLooking for participantsNCT05676450
What this trial is testing

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 517
Not applicableLooking for participantsNCT05595408
What this trial is testing

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Who this might be right for
Muscle Invasive Upper Tract Urothelial Carcinoma
RenJi Hospital 84
Not applicableLooking for participantsNCT06885476
What this trial is testing

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual DiseaseNatural Killer Cell
IRCCS Azienda Ospedaliero-Universitaria di Bologna 22
Testing effectiveness (Phase 2)Looking for participantsNCT06773208
What this trial is testing

Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Next Page
184
60